TY - JOUR
T1 - Endoscopic Management of Idiopathic Subglottic Stenosis
T2 - Factors Affecting Inter-Dilation Interval
AU - Shabani, Sepehr
AU - Hoffman, Matthew R.
AU - Brand, William T.
AU - Dailey, Seth H.
N1 - Publisher Copyright:
© SAGE Publications 2016.
PY - 2017/2
Y1 - 2017/2
N2 - Objective: To describe a homogeneous idiopathic subglottic stenosis (ISS) population undergoing endoscopic balloon dilation and evaluate factors affecting inter-dilation interval (IDI). Methods: Retrospective review of 37 patients. Co-morbidity prevalence versus normal population was evaluated using chi-square tests. Correlations were evaluated using Pearson product moment tests. Independent samples t tests/rank sum tests assessed differences between groups of interest. Results: All patients were female aged 45.9 ± 15.4 years at diagnosis. Four required a tracheotomy during management. Most prevalent co-morbidity was gastroesophageal reflux disease (GERD) (64.9%; P =.036). Body mass indices (BMI) at first and most recent dilation were 29.8 and 30.8 (P =.564). Degree of stenosis before first dilation was 53 ± 14%. Patients underwent 3.8 ± 1.8 dilations (range, 1-11). Average IDI was 635 ± 615 days (range, 49-3130 days), including 556 ± 397 days for patients receiving concomitant steroid injection and 283 ± 36 for those who did not (P =.079). Inter-dilation interval was not correlated with BMI (r = 0.0486; P =.802) or number of co-morbidities (r = 0.225, P =.223). Conclusions: Most patients with ISS can be managed endoscopically, and IDI may be increased with steroid injection. Gastroesophageal reflux disease is a common co-morbidity. Body mass index did not change over time despite potential effects on exercise tolerance; BMI did not affect IDI. Methods to determine optimal timing for next intervention are warranted.
AB - Objective: To describe a homogeneous idiopathic subglottic stenosis (ISS) population undergoing endoscopic balloon dilation and evaluate factors affecting inter-dilation interval (IDI). Methods: Retrospective review of 37 patients. Co-morbidity prevalence versus normal population was evaluated using chi-square tests. Correlations were evaluated using Pearson product moment tests. Independent samples t tests/rank sum tests assessed differences between groups of interest. Results: All patients were female aged 45.9 ± 15.4 years at diagnosis. Four required a tracheotomy during management. Most prevalent co-morbidity was gastroesophageal reflux disease (GERD) (64.9%; P =.036). Body mass indices (BMI) at first and most recent dilation were 29.8 and 30.8 (P =.564). Degree of stenosis before first dilation was 53 ± 14%. Patients underwent 3.8 ± 1.8 dilations (range, 1-11). Average IDI was 635 ± 615 days (range, 49-3130 days), including 556 ± 397 days for patients receiving concomitant steroid injection and 283 ± 36 for those who did not (P =.079). Inter-dilation interval was not correlated with BMI (r = 0.0486; P =.802) or number of co-morbidities (r = 0.225, P =.223). Conclusions: Most patients with ISS can be managed endoscopically, and IDI may be increased with steroid injection. Gastroesophageal reflux disease is a common co-morbidity. Body mass index did not change over time despite potential effects on exercise tolerance; BMI did not affect IDI. Methods to determine optimal timing for next intervention are warranted.
KW - endoscopic balloon dilation
KW - idiopathic subglottic stenosis
KW - laryngotracheal stenosis
UR - http://www.scopus.com/inward/record.url?scp=85009785719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009785719&partnerID=8YFLogxK
U2 - 10.1177/0003489416675357
DO - 10.1177/0003489416675357
M3 - Article
C2 - 27864505
AN - SCOPUS:85009785719
SN - 0003-4894
VL - 126
SP - 96
EP - 102
JO - Annals of Otology, Rhinology and Laryngology
JF - Annals of Otology, Rhinology and Laryngology
IS - 2
ER -